Trials / Completed
CompletedNCT00896064
Evaluation of a Booster Dose of Pneumococcal Vaccine Formulations in Young Adults
A Study to Evaluate Safety and Immunogenicity of a Booster Dose of Two Formulations of GSK Biologicals' Pneumococcal Candidate Vaccine in Healthy Young Adults
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 43 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 41 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of a booster dose of pneumococcal vaccines (GSK 2189242A) in young adults. This protocol posting deals with objectives \& outcome measures of the booster phase. The objectives \& outcome measures of the primary phase are presented in a separate protocol posting (NCT 00707798)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Pneumococcal vaccine GSK2189242A (formulation 1) | One dose will be administered intramuscularly at Study Day 0. |
| BIOLOGICAL | Pneumococcal vaccine GSK2189242A (formulation 2) | One dose will be administered intramuscularly at Study Day 0. |
Timeline
- Start date
- 2009-05-18
- Primary completion
- 2009-08-05
- Completion
- 2009-08-05
- First posted
- 2009-05-11
- Last updated
- 2018-08-17
- Results posted
- 2017-07-19
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT00896064. Inclusion in this directory is not an endorsement.